• Direct.Latest news about the coronavirus
  • Agreements: The packaging of the coronavirus vaccine will be made in Spain after a new agreement between ROVI and Moderna
  • Candidates: Moderna, Oxford, and Johnson and Johnson vaccines provide robust protection, one of them with a single dose

The American multinational Moderna has presented on Wednesday new activity data for its vaccine against Covid-19, which it is testing among more than 30,000 volunteers and whose final results are expected to be ready in November. Specifically, a partial analysis presented in the Advisory Committee on Immunization Practices - integrated in the Centers for Disease Control and Prevention in the United States - reveals that the vaccine is safe and generates an immune response in participants over 55 years of age similar to that of the other age groups.

The information analyzes data from the study that is being carried out with the mRNA-1273 vaccine and whose main conclusion is that at the dose of 100 micrograms the vaccine is generally safe and well tolerated in all age groups, and achieves « comparable immunogenicity in the cohorts aged between 56 and 70 years, and over 71 years, relative to the cohort of younger adults, aged between 18 and 55 years.

The company has also reported that there have been no serious adverse effects related to its administration. At the 100 microgram dose, the vaccine known as mRNA-1273 induced consistently high levels of neutralizing antibody concentrations in all participants in the two oldest age groups; the concentrations, in particular, were two to three times higher than those observed in convalescent serum.

These data are especially important because of the greater vulnerability of the older age groups, and because of the lower activity that some vaccines present precisely in these population groups.

All this new information has been analyzed to deepen the previous knowledge that the company had obtained and that already showed that the vaccine generates a relevant immune response in healthy young volunteers, and it is the company itself that indicates that more data will still be necessary to determine the eventual prevention of coronavirus infection. According to Stephane Bancel, CEO of Moderna, has told Business Insider, "in the best of scenarios, we could know if the vaccine works in October."

At the beginning of the week, Moderna agreed with the EU to supply 80 million vaccines and expandable to an additional 80 million for a total of 160. In Spain, the pharmaceutical company Rovi will be in charge of packaging it. Thus, the product will be ready to go out and supply markets outside the US as of next year, or perhaps well into the fall, as the company points out.

According to the criteria of The Trust Project

Know more

  • Science and Health
  • Vaccinations
  • Covid 19
  • Coronavirus
  • U.S
  • Pharmacology

HealthThe cold could protect you from Covid

The Moderna, Oxford and Johnson and Johnson vaccines provide robust protection and one of them with a single dose

CoronavirusThe WHO, "hopeful" because six candidates for a vaccine against Covid-19 are already in phase 3

See links of interest

  • News
  • Translator
  • Programming
  • Calendar
  • Horoscope
  • Classification
  • Films
  • Cut notes
  • Topics